A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with either JNJ-63723283 (cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503132-14-00

Acronym

78278343PCR1003

Enrollment

Registered

2025-03-10

Start date

2025-06-30

Completion date

Unknown

Last updated

2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Prostate Cancer

None listed

Sex/Gender

Male

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026